StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $7.90 | $7.66 | -3.06% | 1.1M |
| 05-12 | $7.65 | $7.51 | -1.83% | 1.2M |
| 05-13 | $7.53 | $7.50 | -0.40% | 1.1M |
| 05-14 | $8.54 | $7.93 | -7.20% | 4.3M |
| 05-15 | $7.95 | $7.55 | -5.03% | 2.8M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for CRMD.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Metric | Q1 2026 2026-03-31 | Q1 2025 2025-03-31 |
|---|---|---|
Revenue | $127.43M | $39.08M |
Operating Income | $63.66M | $20.13M |
Net Income | $38.60M | $20.64M |
EPS (Diluted) | $0.43 | $0.30 |
Total Assets | $815.64M | $149.58M |
Total Liabilities | $378.59M | $34.69M |
Cash & Equivalents | $178.09M | $66.29M |
Free Cash Flow OCF − CapEx | $41.65M | $19.73M |
Shares Outstanding | 78.40M | 67.71M |
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Fundamentals not available for CRMD.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.